MCB 100 UIUC FINAL EXAM WITH COMPLETE CORR
What cwould cbe cthe cbest cway cto cavoid cresistance cusing can cantimicrobial cdrug? c
A. cUse ca csingle cdrug cthat cacts con ca csingle ctarget. c
B. cUse cmultiple cdrugs cthat cact con cmultiple ctargets. c
C. cUse cmultiple cdrugs cthat cact con ca csingle ctarget. c
D. cUse ca csingle cdrug cthat cacts con cmultiple ctargets. c
E. cNone cof cthese capproaches cwould chelp cavoid cresistance c- cCORRECT cANS✔✔B. cUse cmult
ctargets.
Which cof cthe cfollowing cdoes cnot cexplain cwhy cpathogens care cless clikely cto cdevelop cresistance
cantimicrobial cdrugs? c
A. cVaccines coften ctarget cmultiple cparts cof cthe cpathogen. c
B. cVaccines ckill cmicrobes cmore crapidly cthan cantimicrobial cdrugs. c
C. cVaccines ccan cinvolve cboth chumoral cand ccell-mediated cimmune cresponses. c
D. cVaccines cminimize cthe cchance cof ctransmitting ca cresistant cstrain cof cpathogen. c
E. cVaccines cact cat can cearlier cstage cof cinfection cthan cantimicrobial cdrugs. c- cCORRECT cANS✔
cmore crapidly cthan cantimicrobial cdrugs.
Would cantigenic cdrift cor cantigenic cshift cbe cmore clikely cto ccause cinfluenza cvaccine cfailure? c
A. cAntigenic cdrift c
B. cAntigenic cshift c
C. cThey cwould cbe cequally clikely cto ccause cvaccine cfailure c
D. cNeither cof cthese cprocesses cwould ccause cvaccine cfailure. c
E. cI cforgot cwhat cantigenic cdrift cand cshift cwere csince cthe clast cexam. c- cCORRECT cANS✔✔B. cA
Which cof cthe cfollowing cvaccine capproaches cwould cnot chelp cavoid coriginal cantigenic csin? c
A. cInclude cmultiple cserotypes c(strains) cof cthe csame cpathogen cin cthe cvaccine. c
B. cInclude ca csecond cserotype cof cpathogen cduring cthe csecond cboost cof cthe cvaccine cregimen.
C. cInclude cdendritic ccell cadjuvants cin cthe cvaccine cto cstimulate can cimmune cresponse cto cmultip
D. cInclude cone cspecific cprotein ctarget cfrom cthe cpathogen cin cthe cvaccine. c
E. cInclude cmultiple cserotypes cof ca cpathogen cin ca crecombinant cvaccine. c- cCORRECT cANS✔✔
cprotein ctarget cfrom cthe cpathogen cin cthe cvaccine.
Which cof cthe cfollowing cis cnot ca creason cHIV cis ca cdifficult cvaccine ctarget? c
, A. cEradication crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto czero cnew ccases
cdeliberate cefforts. cElimination crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto c
cdisease cthrough cdeliberate cefforts. c
B. cEradication crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto czero cnew ccases
cdeliberate cefforts. cElimination crefers cto cthe creduction cto czero c(or ca cvery clow cdefined ctarget cra
cdefined cgeographical carea. c
C. cEradication crefers cto cthe creduction cto czero c(or ca cvery clow cdefined ctarget crate) cof cnew ccas
carea. cElimination crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto czero cnew cca
cdeliberate cefforts. c- cCORRECT cANS✔✔B. cEradication crefers cto cthe ccomplete cand cpermanent
cnew ccases cof cthe cdisease cthrough cdeliberate cefforts. cElimination crefers cto cthe creduction cto cz
ctarget crate) cof cnew ccases cin ca cdefined cgeographical carea.
Although cvaccines cused cin cnational cimmunization cprograms care cconsidered csafe cand ceffective
cand cadverse cevents cwill coccasionally coccur cfollowing cvaccination. cPublic ctrust cin cvaccine csafe
cvaccination cprograms. cAn cadverse cevent cfollowing cimmunization cis cany cuntoward cmedical cocc
cwhich cdoes cnot cnecessarily chave ca ccausal crelationship cwith cthe cusage cof cthe cvaccine. cWhich
cstatement cwith cregard cto can cadverse cevent cfollowing cimmunization? c
A. cAn cadverse cevent cfollowing cimmunization ccan cbe cdue cto cany cadverse cvaccine creaction cca
cvaccine-related cevent cwhen cthe cvaccine cadministered ccorrectly. c
B. cAn cadverse cevent cfollowing cimmunization ccan cbe cdue cto can cadverse cvaccine creaction ccau
cadministration cof cthe cvaccine. c
C. cAn cadverse cevent cfollowing cimmunization ccan cbe cdue cto can cadve c- cCORRECT cANS✔✔E.
cimmunization ccan cbe cdue cto can cadverse cvaccine creaction cdue cto cthe ccauses cmentioned cin cA
Vaccines care cnormally cscheduled cin cinfancy cand cearly cchildhood, cwhen cillnesses care ccommon
cneurological cconditions cbecome capparent. cDuring ca cmass cvaccination ccampaign, ccoincidental
cvaccinating cchildren cin cthese cage cgroups. cImmediate cinvestigation cof ca csevere cadverse ceven
cnot ccausally crelated cto cit cis ccritical cin corder cto crespond cto ca ccommunity's cconcern cabout cvac
cpublic cconfidence cin cimmunization. cCalculating cthe cexpected crate cof can cadverse cevent cis cimp
cthe ctable, chow cmany cinfant cdeaths care cexpected cto coccur ccoincidentally c(i.e. cnot clinked cto cth
cday cafter cthe cvaccine cis cadministered? c
A. c18 c
B. c23 c
C. c185 c
D. c2,421 c
E. c16,948 c- cCORRECT cANS✔✔D. c2,421
What cwould cbe cthe cbest cway cto cavoid cresistance cusing can cantimicrobial cdrug? c
A. cUse ca csingle cdrug cthat cacts con ca csingle ctarget. c
B. cUse cmultiple cdrugs cthat cact con ca csingle ctarget. c
C. cUse cmultiple cdrugs cthat cact con cmultiple ctargets. cD. cUse ca csingle cdrug cthat cacts con cmultip
E. cNone cof cthese capproaches cwould chelp cavoid cresistance c- cCORRECT cANS✔✔C. cUse cmult
ctargets.
Which cof cthe cfollowing cdoes cnot cexplain cwhy cpathogens care cless clikely cto cdevelop cresistance
cantimicrobial cdrugs? c
A. cVaccines coften ctarget cmultiple cparts cof cthe cpathogen. c
B. cVaccines ccan cinvolve cboth chumoral cand ccell-mediated cimmune cresponses. c
C. cVaccines cminimize cthe cchance cof ctransmitting ca cresistant cstrain cof cpathogen. c
D. cVaccines cact cat can cearlier cstage cof cinfection cthan cantimicrobial cdrugs. c
E. cVaccines ckill cmicrobes cmore crapidly cthan cantimicrobial cdrugs. c- cCORRECT cANS✔✔E. cVac
What cwould cbe cthe cbest cway cto cavoid cresistance cusing can cantimicrobial cdrug? c
A. cUse ca csingle cdrug cthat cacts con ca csingle ctarget. c
B. cUse cmultiple cdrugs cthat cact con cmultiple ctargets. c
C. cUse cmultiple cdrugs cthat cact con ca csingle ctarget. c
D. cUse ca csingle cdrug cthat cacts con cmultiple ctargets. c
E. cNone cof cthese capproaches cwould chelp cavoid cresistance c- cCORRECT cANS✔✔B. cUse cmult
ctargets.
Which cof cthe cfollowing cdoes cnot cexplain cwhy cpathogens care cless clikely cto cdevelop cresistance
cantimicrobial cdrugs? c
A. cVaccines coften ctarget cmultiple cparts cof cthe cpathogen. c
B. cVaccines ckill cmicrobes cmore crapidly cthan cantimicrobial cdrugs. c
C. cVaccines ccan cinvolve cboth chumoral cand ccell-mediated cimmune cresponses. c
D. cVaccines cminimize cthe cchance cof ctransmitting ca cresistant cstrain cof cpathogen. c
E. cVaccines cact cat can cearlier cstage cof cinfection cthan cantimicrobial cdrugs. c- cCORRECT cANS✔
cmore crapidly cthan cantimicrobial cdrugs.
Would cantigenic cdrift cor cantigenic cshift cbe cmore clikely cto ccause cinfluenza cvaccine cfailure? c
A. cAntigenic cdrift c
B. cAntigenic cshift c
C. cThey cwould cbe cequally clikely cto ccause cvaccine cfailure c
D. cNeither cof cthese cprocesses cwould ccause cvaccine cfailure. c
E. cI cforgot cwhat cantigenic cdrift cand cshift cwere csince cthe clast cexam. c- cCORRECT cANS✔✔B. cA
Which cof cthe cfollowing cvaccine capproaches cwould cnot chelp cavoid coriginal cantigenic csin? c
A. cInclude cmultiple cserotypes c(strains) cof cthe csame cpathogen cin cthe cvaccine. c
B. cInclude ca csecond cserotype cof cpathogen cduring cthe csecond cboost cof cthe cvaccine cregimen.
C. cInclude cdendritic ccell cadjuvants cin cthe cvaccine cto cstimulate can cimmune cresponse cto cmultip
D. cInclude cone cspecific cprotein ctarget cfrom cthe cpathogen cin cthe cvaccine. c
E. cInclude cmultiple cserotypes cof ca cpathogen cin ca crecombinant cvaccine. c- cCORRECT cANS✔✔
cprotein ctarget cfrom cthe cpathogen cin cthe cvaccine.
Which cof cthe cfollowing cis cnot ca creason cHIV cis ca cdifficult cvaccine ctarget? c
, A. cEradication crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto czero cnew ccases
cdeliberate cefforts. cElimination crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto c
cdisease cthrough cdeliberate cefforts. c
B. cEradication crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto czero cnew ccases
cdeliberate cefforts. cElimination crefers cto cthe creduction cto czero c(or ca cvery clow cdefined ctarget cra
cdefined cgeographical carea. c
C. cEradication crefers cto cthe creduction cto czero c(or ca cvery clow cdefined ctarget crate) cof cnew ccas
carea. cElimination crefers cto cthe ccomplete cand cpermanent cworldwide creduction cto czero cnew cca
cdeliberate cefforts. c- cCORRECT cANS✔✔B. cEradication crefers cto cthe ccomplete cand cpermanent
cnew ccases cof cthe cdisease cthrough cdeliberate cefforts. cElimination crefers cto cthe creduction cto cz
ctarget crate) cof cnew ccases cin ca cdefined cgeographical carea.
Although cvaccines cused cin cnational cimmunization cprograms care cconsidered csafe cand ceffective
cand cadverse cevents cwill coccasionally coccur cfollowing cvaccination. cPublic ctrust cin cvaccine csafe
cvaccination cprograms. cAn cadverse cevent cfollowing cimmunization cis cany cuntoward cmedical cocc
cwhich cdoes cnot cnecessarily chave ca ccausal crelationship cwith cthe cusage cof cthe cvaccine. cWhich
cstatement cwith cregard cto can cadverse cevent cfollowing cimmunization? c
A. cAn cadverse cevent cfollowing cimmunization ccan cbe cdue cto cany cadverse cvaccine creaction cca
cvaccine-related cevent cwhen cthe cvaccine cadministered ccorrectly. c
B. cAn cadverse cevent cfollowing cimmunization ccan cbe cdue cto can cadverse cvaccine creaction ccau
cadministration cof cthe cvaccine. c
C. cAn cadverse cevent cfollowing cimmunization ccan cbe cdue cto can cadve c- cCORRECT cANS✔✔E.
cimmunization ccan cbe cdue cto can cadverse cvaccine creaction cdue cto cthe ccauses cmentioned cin cA
Vaccines care cnormally cscheduled cin cinfancy cand cearly cchildhood, cwhen cillnesses care ccommon
cneurological cconditions cbecome capparent. cDuring ca cmass cvaccination ccampaign, ccoincidental
cvaccinating cchildren cin cthese cage cgroups. cImmediate cinvestigation cof ca csevere cadverse ceven
cnot ccausally crelated cto cit cis ccritical cin corder cto crespond cto ca ccommunity's cconcern cabout cvac
cpublic cconfidence cin cimmunization. cCalculating cthe cexpected crate cof can cadverse cevent cis cimp
cthe ctable, chow cmany cinfant cdeaths care cexpected cto coccur ccoincidentally c(i.e. cnot clinked cto cth
cday cafter cthe cvaccine cis cadministered? c
A. c18 c
B. c23 c
C. c185 c
D. c2,421 c
E. c16,948 c- cCORRECT cANS✔✔D. c2,421
What cwould cbe cthe cbest cway cto cavoid cresistance cusing can cantimicrobial cdrug? c
A. cUse ca csingle cdrug cthat cacts con ca csingle ctarget. c
B. cUse cmultiple cdrugs cthat cact con ca csingle ctarget. c
C. cUse cmultiple cdrugs cthat cact con cmultiple ctargets. cD. cUse ca csingle cdrug cthat cacts con cmultip
E. cNone cof cthese capproaches cwould chelp cavoid cresistance c- cCORRECT cANS✔✔C. cUse cmult
ctargets.
Which cof cthe cfollowing cdoes cnot cexplain cwhy cpathogens care cless clikely cto cdevelop cresistance
cantimicrobial cdrugs? c
A. cVaccines coften ctarget cmultiple cparts cof cthe cpathogen. c
B. cVaccines ccan cinvolve cboth chumoral cand ccell-mediated cimmune cresponses. c
C. cVaccines cminimize cthe cchance cof ctransmitting ca cresistant cstrain cof cpathogen. c
D. cVaccines cact cat can cearlier cstage cof cinfection cthan cantimicrobial cdrugs. c
E. cVaccines ckill cmicrobes cmore crapidly cthan cantimicrobial cdrugs. c- cCORRECT cANS✔✔E. cVac
